Oxytocin
البحوث المنشورة وقاعدة الأدلة
Oxytocin is a nine-amino-acid neuropeptide synthesised in the hypothalamus, with intranasal administration used since the mid-2000s as a research tool for probing social cognition, threat processing and affiliative behaviour in humans. The field is unusually large and unusually contested: early small-sample findings of enhanced trust, emotion recognition and amygdala modulation have been followed by large registered trials and preregistered meta-analyses showing small, heterogeneous and frequently null effects. Current syntheses point to sex-dependent amygdala modulation, a thalamus-striatum-insula circuit as the most reproducible neural signature, and a small significant signal in schizophrenia spectrum disorders. Intranasal delivery to the brain, dose-response and the appropriate outcome measures all remain methodologically unresolved.
- الأوكسيتوسين هو ببتيد عصبي من تسعة أحماض أمينية يُصنع في الوطاء.
- أفادت الدراسات بتأثيرات صغيرة وغير متجانسة وغالبًا معدومة على الإدراك الاجتماعي.
- لا يزال التوصيل الأنفي إلى الدماغ والاستجابة للجرعة غير محلولين.
47 دراسة · 21 منذ 2023 · الأحدث 2026
- الدراسات المذكورة
- 47
- منشورة 2023+
- 21
- أحدث ورقة بحثية
- 2026
- آخر مراجعة
- أكتوبر 2026
المواضيع المتكررة في الأدبيات
- social cognition
- intranasal administration
- amygdala reactivity
- autism spectrum disorder trials
- trust and affiliation
- publication bias and replication
- dose-response and inverted-U
- sex differences
- stress and cortisol
معرّفات المركب
- CAS
- 50-56-6
- PubChem
- 439302
ما هو Oxytocin، كيميائياً.
- الصيغة الجزيئية
- C43H66N12O12S2
- الوزن الجزيئي
- 1007.2 g/mol
- رقم CAS
- 50-56-6
- PubChem CID
- 439302
Pitocin, Ocytocin
هذه الأرقام مأخوذة من سجل PubChem لهذا المركب وتصف القاعدة الحرة. يتم توفير الببتيد المجفف بالتجميد عادةً كملح أسيتات أو ترايفلوروأسيتات ويحتوي على ماء متبقٍ، لذا فإن كتلة المسحوق في القارورة ليست نفس الكمية التي يشير إليها الوزن الجزيئي أعلاه. النقاء الكروماتوغرافي في شهادة التحليل لا يحل هذا الفرق أيضاً — كيفية قراءة شهادة التحليل يوضح السبب.
47 دراسة منشورة.
مرتبة حسب قوة تصميم الدراسة، ثم حسب الحداثة. كل إدخال يرتبط بالسجل المصدري حتى يمكن التحقق من النتيجة مقابل الورقة البحثية بدلاً من الاعتماد على كلامنا.
- 01مراجعة منهجية2026
Does intranasal oxytocin reduce symptoms of mental disorders? A meta-analysis of clinical trials
Bonnieux J, et al. · Neuroscience and Biobehavioral Reviews · meta-analysis of 42 double-blind randomised controlled trials, pooled N=1922
The pooled treatment effect was small and non-significant with substantial heterogeneity (g = 0.17, 95% CI -0.05 to 0.38, I-squared 77.4%), falling to g = 0.05 with zero heterogeneity after removing two substance-use-disorder outliers. A small significant effect remained in schizophrenia spectrum disorders (g = 0.12, 95% CI 0.01 to 0.23).
- 02مراجعة منهجية2026
A systematic review and meta-analysis of oxytocin modulation of amygdala responses to emotional stimuli and implications for anxiolytic effects
Guo X, Zhang L, Zhang Q, Kendrick KM, Yao S · Neuroscience and Biobehavioral Reviews · meta-analysis of 55 neuroimaging studies, 3337 participants
Oxytocin's effect on amygdala activity was gender-dependent: inhibition in males and enhancement in females. Activation likelihood estimation showed reduced activity in the centromedial subregion and bidirectional effects in the basolateral subregion.
- 03مراجعة منهجية2026
Effects of exogenous oxytocin on human brain function are regulated by oxytocin gene expression: A meta-analysis of 20 years of oxytocin neuroimaging and transcriptomic analyses
Wang J, et al. · Neuroscience and Biobehavioral Reviews · neuroimaging meta-analysis and transcriptomic analysis across 75 task-fMRI experiments, n=2247
Consistent domain-general effects appeared in left thalamus, pallidum, caudate and insula, but not the amygdala. These regions formed an integrated thalamus-striatum-insula circuit enriched for CD38, OXT and OXTR expression.
- 04مراجعة منهجية2026
Using EEG to Measure the Neural Effects of Oxytocin Administration: A Meta-Analysis and Systematic Review
Deilhaug E, et al. · Psychophysiology · systematic review and meta-analysis of EEG studies of oxytocin administration
The review synthesised electrophysiological evidence for central effects of administered oxytocin, addressing whether EEG provides a more sensitive readout than behavioural endpoints.
- 05مراجعة منهجية2026
Intranasal oxytocin for alcohol use disorder: A systematic review and multilevel, bayesian, and variance meta-analyses of randomized clinical trial data
Santos VH, et al. · Psychoneuroendocrinology · systematic review with multilevel, Bayesian and variance meta-analyses of randomised clinical trial data in alcohol use disorder
The review pooled randomised trial evidence for intranasal oxytocin in alcohol use disorder using multiple synthesis frameworks, addressing the heterogeneity that had driven outlier effects in earlier pooled analyses.
- 06مراجعة منهجية2025
Effects of oxytocin administration on non-social executive functions in humans: a preregistered systematic review and meta-analysis
Kang H, et al. · Molecular Psychiatry · preregistered meta-analysis of 20 effect estimates from 13 eligible studies (PROSPERO CRD42022308149)
There was no overall significant effect on non-social executive function (Hedges' g = 0.07, p = 0.30). A significant effect emerged only for cognitive flexibility (g = 0.2, p = 0.02), with moderate Bayesian support for absence of publication bias.
- 07مراجعة منهجية2025
A multiverse meta-analysis of oxytocin administration studies
Kang H, Deilhaug E, Walle KM, Sartorius AI, Quintana DS · Biological Psychology · 256 distinct meta-analyses across 530 effect sizes from 185 studies, systematically varying inclusion criteria, synthesis models and bias-correction methods
Summary estimates ranged from d = -0.16 to d = 1.45 depending on analytic choices, yet over 90% of the specifications exceeded bootstrapped null distributions. Neurotypical samples and multiple-administration designs yielded larger effects.
- 08مراجعة منهجية2025
Dose-response effects of exogenous oxytocin on social cognition: A systematic review
Barton S, Pruin A, Schulze J, Kiebs M, Scheele D, Hurlemann R · Neuroscience and Biobehavioral Reviews · systematic review of intranasal doses from 1 IU to 48 IU in healthy adults; emotion recognition, empathy and interpersonal trust
Most studies used 24 IU and generally reported improved emotion recognition, empathy and trust, though divergent findings at the same dose occurred. Support for the inverted-U dose-response model came largely from studies lacking direct dose comparisons.
- 09مراجعة منهجية2025
Oxytocin in old age psychiatry: A systematic review of the safety of using intranasal oxytocin in older adults.
Sawares A, et al. · Australas Psychiatry · systematic review of 9 RCTs, n=331 participants aged 60+
Adverse effects of intranasal oxytocin in older adults were predominantly mild and inconsistent across studies, and oxytocin was not significantly associated with severe adverse outcomes after single or short-term repeated use; long-term safety was not assessed.
نتيجة سلامة مُبلغ عنها. No serious adverse events were associated with short-term intranasal oxytocin in adults over 60; long-term safety remains untested.
- 10مراجعة منهجية2024
The effects of oxytocin administration on social and routinized behaviors in autism: A preregistered systematic review and meta-analysis
Audunsdottir K, et al. · Psychoneuroendocrinology · preregistered frequentist and Bayesian meta-analysis of oxytocin administration trials in autism
A small significant effect was found for social outcomes (d = 0.22, p < 0.001) but not routinised behaviours (d = 0.14, p = 0.22). Publication-bias assessments indicated the social effect size may be inflated.
- 11مراجعة منهجية2023
Endogenous oxytocin and human social interactions: A systematic review and meta-analysis
Burenkova OV, et al. · Psychological Bulletin · 63 studies in qualitative synthesis, 51 pooled, n=3741 participants, publications 1970 to July 2020
Social interaction did not produce the expected endogenous oxytocin response in causal designs (pre-post g = 0.079; between-condition g = 0.256), while correlational designs showed a small non-zero association (z = 0.137). The authors called for standardised measurement of oxytocin concentrations.
- 12مراجعة منهجية2023
Effects of intranasal oxytocin on pain perception among human subjects: A systematic literature review and meta-analysis.
Lopes S, Osório FL · Horm Behav · systematic review and meta-analysis, 15 studies, clinical and experimental pain
Intranasal oxytocin had no significant effect on pain intensity (SMD -0.02) or pain unpleasantness (SMD -0.15) compared with placebo.
- 13مراجعة منهجية2018
Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder.
Cai Q, et al. · Psychiatry Clin Neurosci · systematic review and meta-analysis of 5 RCTs, n=223 (123 oxytocin, 100 placebo), autism
Nasal discomfort, tiredness, irritability, diarrhoea and skin irritation were the most common adverse events, none statistically associated with oxytocin; five severe events occurred (aggression: 2 oxytocin, 1 placebo; seizures: 1 in each arm).
نتيجة سلامة مُبلغ عنها. Common adverse events did not differ from placebo; severe events (aggression, seizures) were rare and occurred in both arms.
- 14مراجعة منهجية2011
A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research.
MacDonald E, et al. · Psychoneuroendocrinology · systematic review of 38 RCTs (1990-2010), N=1529 participants, plus search for adverse-reaction reports
Side effects did not differ between oxytocin and placebo, participants could not tell which they had received, and short-term research use was not associated with adverse outcomes; three case reports of adverse reactions involved misuse or longer-term use.
نتيجة سلامة مُبلغ عنها. Short-term research use showed no reliable side effects versus placebo, with three adverse-reaction case reports linked to misuse or longer-term use.
- 15سريري بشري2026
Intranasal Oxytocin for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled Multisite Trial Assessing Efficacy and Safety
Tiouririne NA, et al. · Alcohol, Clinical & Experimental Research · 12-week double-blind placebo-controlled multisite trial, n=100 with alcohol use disorder, up to 70 IU/day intranasal oxytocin
No significant between-group difference was observed in percentage of heavy drinking days over the 10-week maintenance phase, and secondary drinking outcomes followed the same pattern. Participants on oxytocin scored significantly lower on anger and physical aggression at end of treatment, and tolerability was good.
- 16سريري بشري2026
Post-encoding administration of oxytocin selectively enhances memory consolidation of male faces in females
Liu W, Li J, Chen Z, Zhao Q, Sun X · Proceedings of the National Academy of Sciences of the United States of America · three preregistered randomised double-blind placebo-controlled trials, total N=445 (227 male, 218 female), oxytocin given post-encoding, pre-retrieval or pre-encoding
Post-encoding oxytocin, but not pre-retrieval or pre-encoding administration, improved female participants' recognition of male faces 24 h later, with no equivalent effect in males. The authors localised the effect to consolidation rather than encoding or retrieval.
- 17سريري بشري2026
Intranasal Oxytocin and Physical Intimacy for Dermatological Wound Healing and Neuroendocrine Stress: A Randomized Clinical Trial
Schneider E, et al. · JAMA Psychiatry · double-blind randomised placebo-controlled trial, 80 heterosexual couples (N=160, mean age 27.6), 7 days twice-daily oxytocin or placebo with suction-blister wounds and 5-day ecological momentary assessment
Couples receiving oxytocin alongside a structured partner appreciation task showed improved wound healing (b = -0.125, P = .048), though this was not robust in sensitivity analyses. Oxytocin combined with affectionate touch or sexual activity was associated with reduced wound severity, and greater sexual activity with lower daily cortisol.
- 18سريري بشري2026
Intravenous Oxytocin Has no Effect on Ad Libitum Food Intake or Postprandial Plasma Glucose Concentrations in Individuals With Obesity: A Randomised, Placebo-Controlled, Double-Blind, Crossover Study.
Gether IM, et al. · Diabetes Obes Metab · randomised placebo-controlled double-blind crossover study, twenty-four adults with obesity (completers), 4.5-hour intravenous oxytocin versus saline infusion before an ad libitum meal
Ad libitum food intake was similar with oxytocin and saline (714 vs 707 kcal). Oxytocin did not affect appetite sensations, plasma glucose, insulin, C-peptide, glucagon, GLP-1, GIP, cholecystokinin or gastric emptying.
- 19سريري بشري2025
Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial
Coleman KKL, et al. · The Lancet Neurology · adaptive crossover phase 2a/2b trial across 11 clinics in Canada and the USA, 94 participants, 72 IU intranasal oxytocin twice daily on varying schedules vs placebo
Oxytocin every third day improved the Neuropsychiatric Inventory apathy score by an estimated -1.32 points relative to placebo (95% CI -2.43 to -0.21, one-sided p = 0.010) and was well tolerated, with no adverse events attributed to treatment.
- 20سريري بشري2024
The effect of intranasal oxytocin on neurocognition in people with schizophrenia: A randomized controlled trial
İmamoğlu A, Stiles BJ, Jarskog LF, Pedersen CA, Elliott T, Penn DL · Journal of Psychiatric Research · 12-week randomised controlled trial, n=67 participants with schizophrenia or schizoaffective disorder, comprehensive neuropsychological battery at baseline and 12 weeks
Intranasal oxytocin did not significantly improve cognition compared with placebo. The authors noted that timing of cognitive assessment relative to dosing was not standardised.
- 21سريري بشري2024
Effects of four-week intranasal oxytocin administration on large-scale brain networks in older adults
Liu P, et al. · Neuropharmacology · randomised controlled trial of four-week intranasal oxytocin in older adults, resting-state network analysis
Four weeks of intranasal oxytocin altered large-scale brain network organisation in older adults, one of the few chronic-dosing neuroimaging datasets in an ageing sample.
- 22سريري بشري2024
Intranasal Oxytocin for Obesity.
Plessow F, et al. · NEJM Evid · RCT, n=61 adults with obesity, 8 weeks intranasal oxytocin vs placebo
Body weight change did not differ from placebo (0.20 vs 0.26 kg), and there were no benefits on fat mass, visceral or liver fat or resting energy expenditure; caloric intake at a test meal was lower with oxytocin, and adverse events did not differ between groups.
- 23سريري بشري2023
The effect of oxytocin nasal spray on social interaction in young children with autism: a randomized clinical trial.
Guastella AJ, et al. · Mol Psychiatry · double-blind randomised placebo-controlled trial after a 3-week placebo lead-in, n=87 children aged 3-12 years with autism, intranasal oxytocin for 12 weeks
Oxytocin had no overall effect on caregiver-rated social responsiveness (SRS-2, p = 0.686), although an age interaction (p = 0.028) suggested some benefit in children aged 3-5 years. There was no benefit on clinician-rated global improvement or any secondary measure, and adverse effects were reported more often with placebo.
- 24سريري بشري2021
Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder
Sikich L, et al. · The New England Journal of Medicine · 24-week placebo-controlled phase 2 trial, n=290 randomised (146 oxytocin, 144 placebo), ages 3-17, target 48 IU intranasal daily
The least-squares mean change in ABC modified Social Withdrawal score was -3.7 with oxytocin and -3.5 with placebo (difference -0.2, 95% CI -1.5 to 1.0, P = 0.61). Secondary outcomes generally did not differ, making this the definitive negative trial in autism.
- 25سريري بشري2021
Continued versus discontinued oxytocin stimulation in the active phase of labour (CONDISOX): double blind randomised controlled trial.
Boie S, et al. · BMJ · international multicentre double-blind randomised trial (CONDISOX), n=1200 women receiving intravenous oxytocin in induced labour, oxytocin discontinued versus continued in the active phase
Caesarean rates were 16.6% with discontinuation and 14.2% with continuation (relative risk 1.17, 95% CI 0.90 to 1.53). Continued oxytocin shortened labour but was associated with more uterine hyperstimulation (12.9% vs 3.7%) and fetal heart rate abnormalities (40.8% vs 27.9%); other maternal and neonatal outcomes were similar.
نتيجة سلامة مُبلغ عنها. Continued oxytocin infusion was associated with more uterine hyperstimulation and abnormal fetal heart rate patterns than discontinuation.
- 26سريري بشري2021
High-Dose Compared With Standard-Dose Oxytocin Regimens to Augment Labor in Nulliparous Women: A Randomized Controlled Trial.
Son M, et al. · Obstet Gynecol · double-blind randomised trial, n=1003 nulliparous women at or beyond 36 weeks undergoing labour augmentation, high-dose versus standard-dose oxytocin regimens
Caesarean birth occurred in 14.5% with the high-dose and 14.4% with the standard-dose regimen (relative risk 1.01, 95% CI 0.75-1.37). The high-dose regimen shortened labour (9.1 vs 10.5 hours) and lowered clinical chorioamnionitis (10.4% vs 15.6%), with no significant differences in other perinatal outcomes.
- 27سريري بشري2021
Combined Oxytocin and Cognitive Behavioral Social Skills Training for Social Function in People With Schizophrenia.
Buchanan RW, et al. · J Clin Psychopharmacol · 24-week double-blind placebo-controlled randomised trial at 2 sites, n=62 adults with schizophrenia or schizoaffective disorder, intranasal oxytocin or placebo added to cognitive behavioural social skills training, 3-month follow-up
There were no significant group differences in social functioning, positive or negative symptoms, defeatist beliefs or asocial beliefs. Interpretation was complicated by site differences in baseline severity and in improvement.
- 28سريري بشري2021
Intranasal oxytocin as a treatment for chronic pelvic pain: A randomized controlled feasibility study.
Flynn MJ, et al. · Int J Gynaecol Obstet · randomised double-blind within-subject crossover feasibility trial, twenty-one women with chronic pelvic pain (12 with analysable data), 2-week courses of intranasal oxytocin and placebo
Relative to placebo, oxytocin improved pain severity but not pain-related interference, an effect driven by four women with a minimal clinically significant improvement (none on placebo). Adherence was excellent and adverse effects did not differ between oxytocin and placebo.
- 29سريري بشري2020
A registered replication study on oxytocin and trust.
Declerck CH, et al. · Nat Hum Behav · preregistered double-blind placebo-controlled replication (registered report), powered >95%
Oxytocin had no effect on trusting behaviour in the trust game under the minimal-social-contact condition used in the original 2005 study; an exploratory post hoc signal in people low in dispositional trust required confirmation.
- 30سريري بشري2020
Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial.
Yamasue H, et al. · Mol Psychiatry · multicentre randomised double-blind placebo-controlled parallel-group trial in Japan, n=106 adults aged 18-48 with autism spectrum disorder, intranasal oxytocin for 6 weeks
Oxytocin did not differ from placebo on the primary endpoint, ADOS reciprocity, because both groups improved (effect size -0.08, P = .69). Oxytocin reduced ADOS repetitive behaviour and increased gaze fixation on socially relevant regions compared with placebo; adverse event rates did not differ, although one participant had temporary gynaecomastia.
- 31سريري بشري2020
Pain-modulating effects of oxytocin in patients with chronic low back pain.
Boll S, et al. · Neuropharmacology · exploratory randomised placebo-controlled crossover fMRI study, 22 men with chronic low back pain and 22 healthy controls, intranasal oxytocin
During heat pain applied to the lower back, oxytocin versus placebo reduced pain intensity ratings and increased caudate (striatal) BOLD responses in patients relative to controls. Oxytocin had no effect on spontaneously experienced back pain.
- 32سريري بشري2018
Heat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth.
Widmer M, et al. · N Engl J Med · randomised double-blind non-inferiority trial at 23 sites in 10 countries (CHAMPION), n=29,645 women after vaginal birth, intramuscular heat-stable carbetocin versus intramuscular oxytocin; oxytocin was given to the comparator arm
Blood loss of at least 500 ml or use of additional uterotonics occurred in 14.4% of the oxytocin group and 14.5% of the carbetocin group, meeting non-inferiority; blood loss of at least 1000 ml occurred in 1.45% versus 1.51%, where non-inferiority was not shown. Use of additional uterotonics, interventions to stop bleeding and adverse effects did not differ significantly.
- 33سريري بشري2018
Intramuscular versus intravenous oxytocin to prevent postpartum haemorrhage at vaginal delivery: randomised controlled trial.
Adnan N, et al. · BMJ · double-blind placebo-controlled randomised trial, n=1075 women at term aiming for vaginal delivery, intravenous versus intramuscular oxytocin for the third stage of labour
Postpartum haemorrhage (500 mL or more) was not significantly lower with intravenous oxytocin (18.8% vs 23.2%; adjusted odds ratio 0.75, 95% CI 0.55 to 1.03). Severe haemorrhage (4.6% vs 8.1%), blood transfusion (1.5% vs 4.4%) and high-dependency admission (1.7% vs 3.7%) were less frequent with the intravenous route, without more side effects (4.1% vs 5.2%).
- 34سريري بشري2016
The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial.
Yatawara CJ, et al. · Mol Psychiatry · double-blind randomised placebo-controlled crossover trial, thirty-one young children with autism, intranasal oxytocin and placebo for 5 weeks each with a 4-week washout
Compared with placebo, oxytocin significantly improved the primary outcome of caregiver-rated social responsiveness. The nasal spray was well tolerated, and the most common adverse events were thirst, urination and constipation.
- 35سريري بشري2015
A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis.
Cacciotti-Saija C, et al. · Schizophr Bull · double-blind randomised placebo-controlled trial, n=52 people aged 16-35 with early psychosis, intranasal oxytocin or placebo for 6 weeks combined with group social cognition training, 3-month follow-up
Oxytocin showed no benefit over placebo on any primary or secondary outcome, including the Reading the Mind in the Eyes Test, symptom scales and social functioning. An exploratory post hoc analysis linked greater nasal spray use with reduced negative symptoms in the oxytocin group only.
- 36سريري بشري2015
Oxytocin reduces caloric intake in men.
Lawson EA, et al. · Obesity (Silver Spring) · randomised placebo-controlled crossover study, n=25 fasting healthy men, single-dose intranasal oxytocin before a test breakfast
Oxytocin reduced caloric intake, preferentially fat intake, and raised cholecystokinin without changing appetite ratings or other appetite-regulating hormones. Resting energy expenditure was unchanged, while substrate use shifted from carbohydrate to fat and insulin sensitivity improved.
- 37سريري بشري2010
Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double-blind, randomised, non-inferiority trial.
Winikoff B, et al. · Lancet · double-blind randomised non-inferiority trial at four hospitals, n=978 women with primary postpartum haemorrhage after vaginal delivery who had not received prophylactic oxytocin, intravenous oxytocin versus sublingual misoprostol as treatment
Active bleeding was controlled within 20 minutes in 96% of women given oxytocin versus 90% given misoprostol, and additional blood loss of 300 mL or more occurred in 17% versus 30%. Shivering (17% vs 47%) and fever (6% vs 44%) were less common with oxytocin; no women had hysterectomies or died.
- 38سريري بشري2010
Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients.
Feifel D, et al. · Biol Psychiatry · randomised double-blind placebo-controlled crossover trial, nineteen people with schizophrenia and residual symptoms on stable antipsychotics (15 completed), adjunctive intranasal oxytocin for 3 weeks
Oxytocin significantly reduced Positive and Negative Syndrome Scale and Clinical Global Impression-Improvement scores versus placebo at the 3-week end point (p < .001), with no benefit at earlier time points. It was well tolerated, with no adverse effects on patient report or laboratory tests.
- 39سريري بشري2008
Oxytocin increases gaze to the eye region of human faces.
Guastella AJ, et al. · Biol Psychiatry · double-blind randomised placebo-controlled between-subject eye-tracking study, n=52 healthy men, single intranasal dose
Men given oxytocin made more fixations and spent more total gaze time on the eye region of neutral faces than men given placebo.
- 40سريري بشري2007
Oxytocin improves "mind-reading" in humans
Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC · Biological Psychiatry · randomised double-blind placebo-controlled crossover, healthy male volunteers, Reading the Mind in the Eyes Test
Intranasal oxytocin improved performance on the Reading the Mind in the Eyes Test relative to placebo, particularly for difficult items. This established the emotion-recognition paradigm used throughout the subsequent literature.
- 41سريري بشري2005
Oxytocin increases trust in humans
Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E · Nature · placebo-controlled trust game experiment in healthy male volunteers
Intranasal oxytocin increased investors' transfers in a trust game relative to placebo without altering behaviour in a matched risk task. This is the foundational human study of the field; subsequent large replication attempts have not consistently reproduced the effect.
- 42سريري بشري2005
Oxytocin modulates neural circuitry for social cognition and fear in humans.
Kirsch P, et al. · J Neurosci · double-blind placebo-controlled crossover fMRI study, n=15 healthy men, intranasal oxytocin
Compared with placebo, oxytocin reduced amygdala activation to fear-inducing visual stimuli and reduced coupling of the amygdala to brainstem regions involved in autonomic and behavioural fear responses.
- 43سريري بشري2003
Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders.
Hollander E, et al. · Neuropsychopharmacology · randomised double-blind placebo-controlled infusion challenge, n=15 adults with autism or Asperger's disorder, intravenous oxytocin
Repetitive behaviours (need to know, repeating, ordering, need to tell or ask, self-injury and touching) were significantly reduced after oxytocin infusion compared with placebo infusion.
- 44سريري بشري2001
WHO multicentre randomised trial of misoprostol in the management of the third stage of labour.
Gülmezoglu AM, et al. · Lancet · WHO multicentre double-blind randomised trial in hospitals across several countries, women delivering vaginally, intravenous or intramuscular oxytocin (n=9266) versus oral misoprostol (n=9264) in active management of the third stage of labour
Measured blood loss of 1000 mL or more occurred in 3% of women given oxytocin versus 4% given misoprostol (relative risk for misoprostol 1.39, 95% CI 1.19-1.63), and additional uterotonics were needed by 11% versus 15%. Shivering and raised body temperature were more common with misoprostol, and the authors judged oxytocin preferable in hospital settings.
- 45سريري بشري1996
Induction of labor compared with expectant management for prelabor rupture of the membranes at term. TERMPROM Study Group.
Hannah ME, et al. · N Engl J Med · multicentre randomised trial (TERMPROM), n=5041 women with prelabour rupture of membranes at term: induction with intravenous oxytocin, induction with vaginal prostaglandin E2, or expectant management with oxytocin or prostaglandin if needed
Neonatal infection and caesarean rates did not differ significantly among groups (neonatal infection 2.0% after oxytocin induction; caesarean 9.6 to 10.9 percent). Oxytocin induction lowered clinical chorioamnionitis (4.0% vs 8.6%, P<0.001) and postpartum fever (1.9% vs 3.6%) compared with expectant management, and women rated induction more positively.
- 46مراجعة2021
Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research
Quintana DS, et al. · Molecular Psychiatry · methodological review of intranasal oxytocin trial design
The review catalogued dose selection, delivery device, timing, sex and context as major sources of heterogeneity, and set out design recommendations that later preregistered meta-analyses adopted.
- 47مراجعة2016
Intranasal Oxytocin: Myths and Delusions
Leng G, Ludwig M · Biological Psychiatry · critical quantitative review of intranasal delivery pharmacology
The authors argued that the quantity of oxytocin reaching central receptors after intranasal dosing is very small relative to endogenous release, and that many reported behavioural effects are underpowered and statistically fragile.
ما لا تثبته هذه الأدلة.
The proportion of an intranasal dose that reaches central oxytocin receptors has never been directly quantified in humans, and no validated peripheral biomarker of central engagement exists. The largest randomised trial in autism was fully null, effect sizes across domains are small and highly sensitive to analytic choices, dose-response is not established from direct within-study dose comparisons, and effects appear to differ by sex and context in ways not yet predictable at the individual level. There is no approved indication for cognitive or social enhancement.
أسئلة شائعة حول البحث.
- What is oxytocin?
Oxytocin is an endogenous nonapeptide produced in the hypothalamus, with an identified receptor in peripheral tissue and central projections to limbic and brainstem regions. In research it is best known from social-neuroscience studies using intranasal administration in healthy volunteers.
- How settled are the social-behaviour findings?
Not very. The early trust and emotion-recognition results are widely cited but have attracted sustained methodological criticism over sample size, replication, and how much intranasally applied peptide reaches the brain. Current review guidance treats the field as unresolved and calls for pre-registered, larger-sample designs.
- What did the largest randomised trial of intranasal oxytocin in autism find?
It was null. The 24-week placebo-controlled phase 2 trial randomised 290 participants aged 3 to 17 to intranasal oxytocin or placebo at a target of 48 IU daily. The least-squares mean change in the ABC modified Social Withdrawal score was -3.7 with oxytocin and -3.5 with placebo, a difference of -0.2 (95 percent CI -1.5 to 1.0, P = 0.61), and secondary outcomes generally did not separate. A 2024 preregistered meta-analysis found a small significant pooled effect on social outcomes (d = 0.22) that publication-bias assessment suggested may be inflated.
متاح من كتالوجنا
لأغراض البحث فقط. ليس للاستهلاك البشري أو التشخيص أو العلاج أو الوقاية من أي حالة. لا شيء في هذه الصفحة يعتبر نصيحة طبية، ولا ينبغي قراءة أي دراسة ملخصة هنا كتوصية.